Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegpleranib - OphthoTech Corporation

Drug Profile

Pegpleranib - OphthoTech Corporation

Alternative Names: E-10030; E01AJ; Fovista; OAP-030; Pegpleranib sodium; X01E

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Archemix Corporation
  • Developer National Eye Institute; OphthoTech Corporation
  • Class Eye disorder therapies; Oligonucleotides; Peptide aptamers
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Phase I/II Von Hippel-Lindau disease
  • Research Retinoblastoma

Most Recent Events

  • 14 Aug 2017 Efficacy and adverse events data from a phase III OPH 1004 trial in Wet age-related macular degeneration released by OphthoTech
  • 14 Aug 2017 OphthoTech terminates a phase III OPH 1004 trial in Wet age-related macular degeneration due to absence of clinically meaningful visual benefit in Argentina, Australia, Austria, Brazil, Canada, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Latvia, , Norway, Poland, Portugal, Slovakia, Spain, USA (Intravitreous)
  • 26 Jul 2017 Early research in Retinoblastoma in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top